Publication | Closed Access
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years
15
Citations
17
References
2008
Year
Compared with placebo, treatment with EZE for up to 2 years in 1624 patients showed no evidence of increased incidence of AEs with increased treatment duration, while showing sustained effects on LDL-C reduction.
| Year | Citations | |
|---|---|---|
Page 1
Page 1